BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31630149)

  • 1. Nitroglycerin Enhances Cisplatin-Induced Cytotoxicity via AKT Inactivation and Thymidylate Synthase Downregulation in Human Lung Cancer Cells.
    Ko JC; Chen JC; Yen TC; Chen TY; Ma PF; Lin YC; Cheng HH; Taso YC; Lin YW
    Pharmacology; 2020; 105(3-4):209-224. PubMed ID: 31630149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression.
    Ko JC; Zheng HY; Chen WC; Peng YS; Wu CH; Wei CL; Chen JC; Lin YW
    Biochem Pharmacol; 2016 Dec; 122():90-98. PubMed ID: 27666600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells.
    Tung CL; Chen JC; Wu CH; Peng YS; Chen WC; Zheng HY; Jian YJ; Wei CL; Cheng YT; Lin YW
    Exp Cell Res; 2017 Aug; 357(1):59-66. PubMed ID: 28454878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
    Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
    Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
    Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
    Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
    Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
    Ko JC; Tsai MS; Chiu YF; Weng SH; Kuo YH; Lin YW
    J Pharmacol Exp Ther; 2011 Jul; 338(1):184-94. PubMed ID: 21444628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells.
    Ko JC; Chen JC; Tseng PY; Hsieh JM; Chiang CS; Liu LL; Chien CC; Huang IH; Lin YW
    Toxicol Res (Camb); 2022 Apr; 11(2):299-310. PubMed ID: 35510237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.
    Ko JC; Syu JJ; Chen JC; Wang TJ; Chang PY; Chen CY; Jian YT; Jian YJ; Lin YW
    Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):383-91. PubMed ID: 26046675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells.
    Ko JC; Chen JC; Wang TJ; Zheng HY; Chen WC; Chang PY; Lin YW
    Biochem Pharmacol; 2016 Apr; 105():91-100. PubMed ID: 26921637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
    Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
    Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
    Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
    Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells.
    Wang M; Liu ZM; Li XC; Yao YT; Yin ZX
    J Chemother; 2013 Jun; 25(3):162-9. PubMed ID: 23783141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
    Ko JC; Chiu HC; Syu JJ; Jian YJ; Chen CY; Jian YT; Huang YJ; Wo TY; Lin YW
    Biochem Pharmacol; 2014 Mar; 88(1):119-27. PubMed ID: 24447935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway.
    Sun Y; Chen Y; Xu M; Liu C; Shang H; Wang C
    Biomed Res Int; 2020; 2020():9243681. PubMed ID: 32685545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
    Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
    Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.